patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_734306 | REC_0002301 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 11.6 | 68 | female | 1 | 10 | 4.2 | 4 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:57.412190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648602 | REC_0002302 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 37 | 4.5 | 68 | female | 1 | 15 | 7.2 | 9 | pembrolizumab 200 mg q3w | 15.7 | false | MSS | 2026-03-15T05:35:57.412558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522449 | REC_0002303 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.6 | 62 | female | 1 | 25 | 5 | 7 | pembrolizumab 200 mg q3w | 11.4 | false | MSS | 2026-03-15T05:35:57.412811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330247 | REC_0002304 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 35 | 11.6 | 65 | female | 1 | 16 | 6.1 | 1 | alectinib 600 mg BID | 15.8 | false | MSS | 2026-03-15T05:35:57.413048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254523 | REC_0002305 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 6.4 | 61 | male | 1 | 22 | 4.5 | 1 | osimertinib 80 mg daily | 20.5 | false | MSS | 2026-03-15T05:35:57.413283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923449 | REC_0002306 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.4 | 53 | female | 0 | 43 | 7.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:35:57.413516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940211 | REC_0002307 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 14.3 | 64 | female | 0 | 10 | 4.5 | 6 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:57.413752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361016 | REC_0002308 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.7 | 47 | male | 0 | 3 | 6.2 | 5 | alectinib 600 mg BID | 6.3 | true | MSS | 2026-03-15T05:35:57.413989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558793 | REC_0002309 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 7.8 | 58 | male | 1 | 10 | 3.5 | 2 | sotorasib 960 mg daily | 23.7 | true | MSS | 2026-03-15T05:35:57.414220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475336 | REC_0002310 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 8.7 | 76 | female | 0 | 8 | 5.5 | 1 | alectinib 600 mg BID | 6 | true | MSS | 2026-03-15T05:35:57.414453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858079 | REC_0002311 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.2 | 59 | male | 0 | 17 | 6.5 | 7 | alectinib 600 mg BID | 13.6 | true | MSI-H | 2026-03-15T05:35:57.414689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493269 | REC_0002312 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 10.5 | 55 | female | 1 | 15 | 6.8 | 2 | sotorasib 960 mg daily | 15.6 | true | MSI-H | 2026-03-15T05:35:57.414923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712037 | REC_0002313 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 10.4 | 81 | female | 1 | 6 | 4.6 | 2 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:57.415166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816594 | REC_0002314 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 10.4 | 73 | female | 1 | 13 | 4.8 | 1 | osimertinib 80 mg daily | 17.2 | true | MSS | 2026-03-15T05:35:57.415403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809959 | REC_0002315 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 3.9 | 69 | female | 1 | 54 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.7 | false | MSS | 2026-03-15T05:35:57.415691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602758 | REC_0002316 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 14.8 | 82 | female | 1 | 15 | 5.4 | 9 | entrectinib 600 mg daily | 19.1 | true | MSI-H | 2026-03-15T05:35:57.415935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244214 | REC_0002317 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14.4 | 56 | female | 1 | 11 | 4.7 | 5 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:57.416266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646340 | REC_0002318 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.6 | 72 | female | 1 | 16 | 5.6 | 8 | carboplatin + paclitaxel + pembrolizumab | 7.3 | true | MSS | 2026-03-15T05:35:57.416510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209086 | REC_0002319 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 8.4 | 57 | male | 0 | 11 | 4.7 | 2 | osimertinib 80 mg daily | 26.9 | false | MSS | 2026-03-15T05:35:57.416747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539655 | REC_0002320 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 15.3 | 65 | female | 1 | 12 | 5.7 | 2 | alectinib 600 mg BID | 25.8 | true | MSI-H | 2026-03-15T05:35:57.416981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552643 | REC_0002321 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 13 | 63 | male | 1 | 12 | 7 | 3 | sotorasib 960 mg daily | 6.4 | true | MSI-H | 2026-03-15T05:35:57.417222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947284 | REC_0002322 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 14 | 7.7 | 76 | female | 2 | 50 | 7.8 | 1 | pembrolizumab 200 mg q3w | 21.9 | false | MSS | 2026-03-15T05:35:57.417452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201362 | REC_0002323 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 14.3 | 70 | female | 2 | 26 | 5.7 | 6 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:57.417685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486266 | REC_0002324 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 10.3 | 76 | female | 2 | 14 | 5.7 | 1 | alectinib 600 mg BID | 7.9 | false | MSI-H | 2026-03-15T05:35:57.417923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784741 | REC_0002325 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 8.5 | 66 | female | 1 | 40 | 5.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:35:57.418152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396591 | REC_0002326 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.5 | 73 | female | 0 | 31 | 5.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:35:57.418379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784058 | REC_0002327 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 6.6 | 87 | female | 2 | 50 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.3 | true | MSS | 2026-03-15T05:35:57.418609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195216 | REC_0002328 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 6.5 | 64 | male | 0 | 12 | 5.7 | 1 | osimertinib 80 mg daily | 13.9 | true | MSS | 2026-03-15T05:35:57.418941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737553 | REC_0002329 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 7.1 | 56 | female | 1 | 17 | 3.8 | 7 | alectinib 600 mg BID | 9.4 | false | MSS | 2026-03-15T05:35:57.419208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_619508 | REC_0002330 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 8.2 | 73 | female | 2 | 54 | 5.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:57.419477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246240 | REC_0002331 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 14.7 | 75 | female | 3 | 11 | 5.6 | 1 | entrectinib 600 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:57.419740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676601 | REC_0002332 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 9.3 | 73 | female | 2 | 28 | 5.2 | 6 | osimertinib 80 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:57.419979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493798 | REC_0002333 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.2 | 72 | female | 2 | 22 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.5 | false | MSS | 2026-03-15T05:35:57.420276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393310 | REC_0002334 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 23 | 5.7 | 73 | male | 2 | 18 | 4.3 | 0 | pembrolizumab 200 mg q3w | 59 | false | MSS | 2026-03-15T05:35:57.420524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493481 | REC_0002335 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15 | 69 | female | 0 | 23 | 5.7 | 8 | osimertinib 80 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:57.420765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984318 | REC_0002336 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 10.6 | 60 | male | 0 | 15 | 4.7 | 7 | pembrolizumab 200 mg q3w | 10.1 | true | MSI-H | 2026-03-15T05:35:57.420999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764987 | REC_0002337 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 11.3 | 85 | female | 2 | 11 | 5.2 | 6 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:57.421231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957939 | REC_0002338 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 13.9 | 72 | male | 2 | 13 | 5.2 | 6 | pembrolizumab 200 mg q3w | 16.5 | true | MSI-H | 2026-03-15T05:35:57.421468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224034 | REC_0002339 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 6.6 | 59 | male | 0 | 10 | 5.5 | 2 | alectinib 600 mg BID | 20.4 | false | MSS | 2026-03-15T05:35:57.421703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435721 | REC_0002340 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.2 | 71 | female | 2 | 24 | 7.3 | 6 | osimertinib 80 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:57.421935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766917 | REC_0002341 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.1 | 70 | female | 2 | 23 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:35:57.422276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649807 | REC_0002342 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11.9 | 63 | male | 1 | 19 | 4.7 | 1 | sotorasib 960 mg daily | 31.5 | false | MSS | 2026-03-15T05:35:57.422522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162770 | REC_0002343 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 9.1 | 80 | female | 2 | 15 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.7 | true | MSS | 2026-03-15T05:35:57.422753+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501925 | REC_0002344 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 10.7 | 57 | female | 1 | 19 | 5.8 | 1 | osimertinib 80 mg daily | 17.1 | true | MSS | 2026-03-15T05:35:57.422989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244505 | REC_0002345 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 16.6 | 68 | female | 0 | 17 | 4.9 | 5 | pembrolizumab 200 mg q3w | 11.8 | false | MSS | 2026-03-15T05:35:57.423222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289143 | REC_0002346 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 6.1 | 51 | female | 0 | 39 | 5.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:57.423456+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665390 | REC_0002347 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 14.8 | 57 | male | 1 | 17 | 5.6 | 4 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:57.423691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510430 | REC_0002348 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 4.9 | 76 | female | 1 | 14 | 7 | 6 | entrectinib 600 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:57.423919+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911801 | REC_0002349 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 14.5 | 65 | male | 1 | 20 | 5.6 | 2 | pembrolizumab 200 mg q3w | 20.6 | false | MSS | 2026-03-15T05:35:57.424213+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978906 | REC_0002350 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 13.9 | 64 | female | 0 | 18 | 6.2 | 1 | sotorasib 960 mg daily | 25.9 | false | MSS | 2026-03-15T05:35:57.424458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673016 | REC_0002351 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.4 | 71 | female | 2 | 19 | 5.5 | 0 | sotorasib 960 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:35:57.424695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_959028 | REC_0002352 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 12.1 | 66 | female | 0 | 23 | 5.1 | 5 | entrectinib 600 mg daily | 10.1 | true | MSI-H | 2026-03-15T05:35:57.424932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914365 | REC_0002353 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 12.8 | 79 | female | 2 | 14 | 7.1 | 6 | entrectinib 600 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:57.425165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412801 | REC_0002354 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.1 | 67 | female | 1 | 0 | 6.5 | 8 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:35:57.425445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387925 | REC_0002355 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 6 | 70 | female | 2 | 26 | 7.6 | 0 | osimertinib 80 mg daily | 44.4 | true | MSS | 2026-03-15T05:35:57.425679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426916 | REC_0002356 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.9 | 64 | male | 0 | 14 | 5.2 | 5 | alectinib 600 mg BID | 7.6 | false | MSS | 2026-03-15T05:35:57.425909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372916 | REC_0002357 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.4 | 66 | male | 0 | 4 | 4.4 | 5 | sotorasib 960 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:57.426142+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416344 | REC_0002358 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 15.8 | 58 | male | 0 | 10 | 7.1 | 8 | sotorasib 960 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:57.426377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842184 | REC_0002359 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 17.3 | 57 | male | 1 | 2 | 3.1 | 4 | entrectinib 600 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:57.426615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274423 | REC_0002360 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12.3 | 77 | female | 1 | 16 | 6.7 | 5 | osimertinib 80 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:57.426849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115168 | REC_0002361 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 16.7 | 61 | male | 1 | 24 | 4.4 | 1 | sotorasib 960 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:57.427083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609272 | REC_0002362 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 14.6 | 56 | female | 0 | 22 | 6.9 | 4 | entrectinib 600 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:57.427318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826128 | REC_0002363 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.7 | 53 | female | 0 | 15 | 5.1 | 6 | osimertinib 80 mg daily | 8 | false | MSS | 2026-03-15T05:35:57.427548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800673 | REC_0002364 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 14 | 4.3 | 58 | female | 0 | 48 | 4.8 | 7 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:57.427778+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533731 | REC_0002365 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 11.5 | 76 | male | 1 | 24 | 3.6 | 7 | pembrolizumab 200 mg q3w | 7.5 | true | MSS | 2026-03-15T05:35:57.428013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374286 | REC_0002366 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 12.3 | 79 | female | 2 | 12 | 5.7 | 6 | sotorasib 960 mg daily | 10 | false | MSI-H | 2026-03-15T05:35:57.428288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191926 | REC_0002367 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 4.3 | 67 | female | 0 | 26 | 5.4 | 7 | osimertinib 80 mg daily | 7 | false | MSS | 2026-03-15T05:35:57.428570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952501 | REC_0002368 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 13.2 | 84 | female | 1 | 20 | 5.6 | 7 | osimertinib 80 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:57.428804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539649 | REC_0002369 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 18.6 | 63 | male | 1 | 14 | 6 | 5 | osimertinib 80 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:57.429042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763501 | REC_0002370 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 13.8 | 72 | male | 1 | 16 | 3.7 | 6 | entrectinib 600 mg daily | 11.3 | false | MSI-H | 2026-03-15T05:35:57.429280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888730 | REC_0002371 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.6 | 73 | female | 1 | 66 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.1 | true | MSS | 2026-03-15T05:35:57.429512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316900 | REC_0002372 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11 | 63 | male | 0 | 19 | 6 | 2 | entrectinib 600 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:35:57.429748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809972 | REC_0002373 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 5.6 | 65 | male | 1 | 11 | 5.4 | 1 | alectinib 600 mg BID | 23.3 | true | MSS | 2026-03-15T05:35:57.429978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838261 | REC_0002374 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 8.9 | 79 | female | 2 | 20 | 4.7 | 1 | osimertinib 80 mg daily | 21.3 | false | MSS | 2026-03-15T05:35:57.430208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548580 | REC_0002375 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 13.2 | 76 | female | 2 | 21 | 4.8 | 1 | osimertinib 80 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:57.430441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140877 | REC_0002376 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 14.4 | 59 | female | 0 | 12 | 6.3 | 7 | entrectinib 600 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:57.430677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624748 | REC_0002377 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 15.2 | 68 | female | 1 | 16 | 6.7 | 4 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.430910+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513137 | REC_0002378 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 17.6 | 54 | male | 0 | 12 | 6.5 | 1 | osimertinib 80 mg daily | 23.6 | true | MSI-H | 2026-03-15T05:35:57.431143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106636 | REC_0002379 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 6.1 | 65 | female | 1 | 19 | 4.1 | 1 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:57.431373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890788 | REC_0002380 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 6 | 78 | female | 2 | 3 | 4.8 | 5 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:57.431665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783422 | REC_0002381 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 14.1 | 65 | female | 1 | 16 | 4.5 | 2 | osimertinib 80 mg daily | 22.9 | true | MSI-H | 2026-03-15T05:35:57.431903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267008 | REC_0002382 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 2.5 | 78 | female | 2 | 16 | 7.6 | 1 | pembrolizumab 200 mg q3w | 30 | true | MSS | 2026-03-15T05:35:57.432223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929360 | REC_0002383 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 11.6 | 53 | female | 0 | 9 | 6.8 | 0 | osimertinib 80 mg daily | 49.8 | false | MSS | 2026-03-15T05:35:57.432479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162709 | REC_0002384 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 13.8 | 83 | female | 1 | 28 | 5.8 | 2 | sotorasib 960 mg daily | 22.9 | true | MSS | 2026-03-15T05:35:57.432712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791778 | REC_0002385 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 18.4 | 66 | female | 1 | 13 | 3.4 | 1 | osimertinib 80 mg daily | 20.5 | true | MSI-H | 2026-03-15T05:35:57.432950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725193 | REC_0002386 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 39 | 3.6 | 64 | male | 1 | 17 | 6.7 | 1 | pembrolizumab 200 mg q3w | 23.7 | false | MSS | 2026-03-15T05:35:57.433182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340083 | REC_0002387 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 16 | 66 | female | 1 | 9 | 5.4 | 2 | entrectinib 600 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:57.433415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988286 | REC_0002388 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.6 | 77 | female | 1 | 28 | 5 | 3 | sotorasib 960 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:35:57.433645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_211921 | REC_0002389 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 17.4 | 77 | female | 2 | 5 | 4.2 | 2 | sotorasib 960 mg daily | 16.2 | true | MSI-H | 2026-03-15T05:35:57.433877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425025 | REC_0002390 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 8.2 | 48 | female | 0 | 27 | 4.8 | 4 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:35:57.434106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751759 | REC_0002391 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6 | 64 | female | 1 | 13 | 6.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:35:57.434339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344570 | REC_0002392 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 7.2 | 59 | female | 0 | 11 | 5.7 | 6 | alectinib 600 mg BID | 5.2 | false | MSS | 2026-03-15T05:35:57.434573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916671 | REC_0002393 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.1 | 76 | male | 2 | 11 | 5.2 | 5 | osimertinib 80 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:57.434863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126422 | REC_0002394 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 14.6 | 61 | female | 1 | 21 | 5.3 | 1 | osimertinib 80 mg daily | 24.7 | false | MSS | 2026-03-15T05:35:57.435106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436342 | REC_0002395 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.3 | 69 | male | 0 | 17 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:57.435339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147701 | REC_0002396 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 8.6 | 72 | female | 1 | 10 | 5.2 | 2 | alectinib 600 mg BID | 24.3 | true | MSS | 2026-03-15T05:35:57.435567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450593 | REC_0002397 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 5.4 | 87 | female | 1 | 21 | 5.3 | 6 | pembrolizumab 200 mg q3w | 6.3 | false | MSS | 2026-03-15T05:35:57.435792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109253 | REC_0002398 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 14.8 | 71 | female | 2 | 12 | 3.9 | 2 | entrectinib 600 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:57.436026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_787721 | REC_0002399 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 7.7 | 72 | female | 2 | 44 | 7.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.2 | false | MSS | 2026-03-15T05:35:57.436363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230956 | REC_0002400 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 5.8 | 75 | male | 2 | 13 | 6.5 | 1 | osimertinib 80 mg daily | 21.9 | false | MSS | 2026-03-15T05:35:57.436604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.